Philips Stock Sinks To 52-Week Low - Here's Why
Koninklijke Philips N.V. (NYSE: PHG ) stock declined in Tuesday’s session after the company beat second-quarter earnings estimates but reported weaker order intake, continued challenges in China and underlying margin pressure obscured by a U.S. tariff refund. The healthcare technology company reported adjusted earnings of 57 cents per share, beating the consensus of 40 cents. Sales reached $5.068 billion (4.36 billion euros), slightly above the consensus of $5.040 billion. Comparable sales increased by 4%, driven by growth across all segments. A 186 million euros U.S. tariff refund boosted reported profitability, masking underlying margin pressure in the Diagnosis & Treatment unit from inflation, tariffs, and an unfavorable sales mix. Read Also: GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Isn’t He Speaking Out&#...
V. S. tariff refund. The healthcare technology company reported adjusted earnings of 57 cents per share, beating the consensus of 40 cents.
040 billion. Comparable sales increased by 4%, driven by growth across all segments. S. tariff refund boosted reported profitability, masking underlying margin pressure in the Diagnosis & Treatment unit from inflation, tariffs, and an unfavorable sales mix.
24 Billion Pfizer COVID Vaccine Contracts: 'Why Isn’t He Speaking Out' Order Intake Declines Comparable order intake declined 1%, with growth in Diagnosis & Treatment offset by the timing of certain large Connected Care orders shifting into the third quarter. 2%. Adjusted EBITA excluding the tariff refund slightly decreased, mainly due to cost inflation and higher tariffs, partly offset by higher sales and productivity measures. 085 billion euros.
Comparable sales increased by 2%, led by high-single-digit growth in Image Guided Therapy, partly offset by a low-single-digit decline in Precision Diagnosis. During the earnings call, the executives said weakness in China affected Diagnosis & Treatment margins in the second quarter, as centralized procurement and subdued hospital investment continued to pressure the market. 184 billion euros. Comparable sales increased by 2%, mainly driven by mid-single-digit growth in Monitoring.
Personal Health sales were 909 million euros. Comparable sales increased by 8%, driven by double-digit growth in Growth geographies and mid-single-digit growth in Mature geographies. 5%. Guidance reflects that Diagnosis & Treatment segment growth is at the lower end, while Connected Care and Personal Health are at the upper end.
Philips expects Greater China sales to remain broadly stable. S. tariff refund. Excluding the refund, the underlying outlook remains unchanged.
57 at the time of publication on Tuesday. The stock is trading at a new 52-week low, according to Pro data. Photo by Mats Wiklund via Shutterstock Read Also: Box CEO Aaron Levie Says AI Is Creating New Hiring Opportunities, Not the 'Negative AI Jobs Outcome' Many Predicted